Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Immuno-oncology drug development forges on despite COVID-19.

Literature DB >> 32948858

Immuno-oncology drug development forges on despite COVID-19.

Samik Upadhaya, Vanessa M Hubbard-Lucey, Jia Xin Yu.

Abstract

Entities: Disease

Mesh：

Year: 2020 PMID： 32948858 DOI： 10.1038/d41573-020-00166-1

Source DB: PubMed Journal: Nat Rev Drug Discov ISSN： 1474-1776 Impact factor: 84.694

Keyword Cloud
Cited

× No keyword cloud information.

23 in total

1. Emergency Department Visits for Emesis Following Chemotherapy: Guideline Nonadherence, OP-35, and a Path Back to the Future.

Authors: Alfred I Neugut; Susan E Bates
Journal: Oncologist Date: 2021-03-04

2. A single local delivery of paclitaxel and nucleic acids via an immunoactive polymer eliminates tumors and induces antitumor immunity.

Authors: Fanfei Meng; Jianping Wang; Yanying He; Gregory M Cresswell; Nadia A Lanman; L Tiffany Lyle; Timothy L Ratliff; Yoon Yeo
Journal: Proc Natl Acad Sci U S A Date: 2022-05-24 Impact factor: 12.779

3. Combined analysis of T cell activation and T cell-mediated cytotoxicity by imaging cytometry.

Authors: Monica K Chanda; Claire E Shudde; Taylor L Piper; Yating Zheng; Adam H Courtney
Journal: J Immunol Methods Date: 2022-05-27 Impact factor: 2.287

4. Optimal long peptide for flagellin-adjuvanted HPV E7 cancer vaccine to enhance tumor suppression in combination with anti-PD-1.

Authors: Hye Hwa Lee; Seol Hee Hong; Joon Haeng Rhee; Shee Eun Lee
Journal: Transl Cancer Res Date: 2022-06 Impact factor: 0.496

5. "You have to be sure that the patient has the full picture": Adaptation of the Best Case/Worst Case communication tool for geriatric oncology.

Authors: Melisa L Wong; Francesca M Nicosia; Alexander K Smith; Louise C Walter; Vivian Lam; Harvey Jay Cohen; Kah Poh Loh; Supriya G Mohile; Carling J Ursem; Margaret L Schwarze
Journal: J Geriatr Oncol Date: 2022-02-02 Impact factor: 3.929

Review 10. Telomerase as a Target for Therapeutic Cancer Vaccines and Considerations for Optimizing Their Clinical Potential.

Authors: Espen Basmo Ellingsen; Sara M Mangsbo; Eivind Hovig; Gustav Gaudernack
Journal: Front Immunol Date: 2021-07-05 Impact factor: 7.561

Immuno-oncology drug development forges on despite COVID-19.

1. Emergency Department Visits for Emesis Following Chemotherapy: Guideline Nonadherence, OP-35, and a Path Back to the Future.

2. A single local delivery of paclitaxel and nucleic acids via an immunoactive polymer eliminates tumors and induces antitumor immunity.

3. Combined analysis of T cell activation and T cell-mediated cytotoxicity by imaging cytometry.

4. Optimal long peptide for flagellin-adjuvanted HPV E7 cancer vaccine to enhance tumor suppression in combination with anti-PD-1.

5. "You have to be sure that the patient has the full picture": Adaptation of the Best Case/Worst Case communication tool for geriatric oncology.

Review 6. How Do We Meet the Challenge of Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors?

Review 7. Cationic Nanoparticle-Based Cancer Vaccines.

8. Cancer immunotherapy: recent advances and challenges.

Review 9. Harnessing Tumor Necrosis Factor Alpha to Achieve Effective Cancer Immunotherapy.

Review 10. Telomerase as a Target for Therapeutic Cancer Vaccines and Considerations for Optimizing Their Clinical Potential.